Spinout Active LTD

Company profile

Marrabio Limited

UK company 14289165, incorporated on 10 August 2022.

MarraBio Building Better Biology

Marrabio Limited is a UK company with status Active founded in 2022 based in North East England.

Company number
14289165
Incorporated
10 Aug 2022
Companies House status
Active

Company identity

Browse spinouts
Founded / incorporated
10 August 2022

Company number 14289165

Verify at Companies House
Legal name
MARRABIO LIMITED
Company type
Private Limited Company
Region
North East England
Registered address
SANDGATE HOUSE
102 QUAYSIDE
NEWCASTLE UPON TYNE
TYNE AND WEAR
ENGLAND
NE1 3DX
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Marrabio Limited
CRN 14289165
2
Direct and ultimate controller Active LTD

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
9

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

24 Aug
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzU0MDUzMjcwNmFkaXF6a2N4

Published 24 Aug 2026 10:19

23 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

09 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

10 Aug
2022

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2023
Funded years
2023, 2025
Age at first award
1 years

Projects

2025 Collaborative R&D

Translating Angicyte® from allogeneic to autologous – a robust development process for a low-cost vascular therapy for personalised medicine

1 Jun 2025 to 31 May 2026

Awarded
£69,840
Total cost £99,771

**Public Description** **A regenerative medicine for vascular disease** VascVersa is developing a groundbreaking cell therapy known as Angicyte, designed to treat vascular ischaemic diseases, which are conditions caused by insufficient blood supply to tissues. Angicyte works by stimulating the formation of new blood vessels in areas with low oxygen levels...

2023 Collaborative R&D Lead participant

High potency food grade growth factor mimics for low cost cultivated meat manufacture

1 Oct 2023 to 31 Dec 2024

Awarded
£139,994
Total cost £199,991

Cultivated meat promises to revolutionize the food industry by providing a more ethical and greener alternative to animal products, whilst retaining the same taste and texture. However, these products are being held back by the technical complexity of production and, in particular, the high cost of materials used in their manufacture. It is estimated that...

2023 Collaborative R&D

Developing novel animal cell lines and processes incoperating engineered caf1 to scale cultured meat protein manufacturing

1 Oct 2023 to 31 Mar 2025

Awarded
£111,416
Total cost £159,166

World meat consumption has tripled since 1970 and will increase a further 76% by 2050, posing a significant sustainability challenge. Livestock farming contributes to 15% of human-made greenhouse gas (GHG) emissions, which further exacerbates climate change, environmental destruction, and infectious disease outbreaks. Cultivated meat (CM) is an approach t...

2023 Collaborative R&D

Tools and technologies for cultured meat production

1 Oct 2023 to 30 Sep 2025

Awarded
£46,354
Total cost £66,220

World meat consumption has tripled since 1970 and will increase a further 76% by 2050\. In the future, there will not be enough meat available for the world's population. This shortage will hit low-and-middle-income countries, where meat is an important but limited source of nutrient-dense protein, vitamins and minerals, especially hard. Over 80 billion a...

Product types

Collaborative R&D